Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study-Reference-Cited by-同舟云学术

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study

Published:2014-06 Issue:6 Volume:2 Page:455-463
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Sjouke Barbara,Langslet Gisle,Ceska Richard,Nicholls Stephen J,Nissen Steven E,Öhlander Maria,Ladenson Paul W,Olsson Anders G,Hovingh G Kees,Kastelein John J P

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference32 articles.

1. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society;Nordestgaard;Eur Heart J,2013

2. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult;Anderson;Can J Cardiol,2013

3. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands;Pijlman;Atherosclerosis,2010

4. ESC/EAS guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS);Catapano;Atherosclerosis,2011

5. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal;Huijgen;PLoS One,2010

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beneficial effects of MGL‐3196 and BAM15 combination in a mouse model of fatty liver disease;Acta Physiologica;2024-08-16

2. Drug discovery targeting thyroid hormone receptor β (THRβ) for the treatment of liver diseases and other medical indications;Acta Pharmaceutica Sinica B;2024-08

3. Potential therapeutic strategies for MASH: from preclinical to clinical development;Life Metabolism;2024-07-06

4. Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2024-05

5. Selective Agonists of Thyroid Hormone Receptor Beta: Promising Tools for the Treatment of Nonalcoholic Fatty Liver Disease;Endocrinology and Metabolism;2024-04-30